FDA Inspection 1202777 — Octapharma Plasma Inc
The FDA completed an inspection of Octapharma Plasma Inc on April 7, 2023 in Dayton, OH. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- April 7, 2023
- Fiscal Year
- 2023
- Product Type
- Biologics
- Project Area
- Blood and Blood Products
- Location
- Dayton, OH (United States)